CN Stock MarketDetailed Quotes

300937 Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical

Watchlist
  • 31.63
  • +0.13+0.41%
Market Closed Dec 13 15:00 CST
3.03BMarket Cap129.63P/E (TTM)

Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
Total operating revenue
0.72%3.24B
0.93%2.23B
10.29%1.24B
11.62%4.43B
19.75%3.21B
25.40%2.2B
23.29%1.12B
16.72%3.97B
11.49%2.68B
10.35%1.76B
Operating revenue
0.72%3.24B
0.93%2.23B
10.29%1.24B
11.62%4.43B
19.75%3.21B
25.40%2.2B
23.29%1.12B
16.72%3.97B
11.49%2.68B
10.35%1.76B
Other operating revenue
----
48.84%15.08M
----
-0.48%23.54M
----
7.48%10.13M
----
45.73%23.65M
----
719.53%9.43M
Total operating cost
2.52%3.21B
3.23%2.2B
13.84%1.22B
11.20%4.34B
18.18%3.13B
23.03%2.13B
19.52%1.07B
14.98%3.91B
10.66%2.65B
9.47%1.73B
Operating cost
1.12%2.96B
2.27%2.04B
13.28%1.14B
11.19%4.06B
17.40%2.92B
22.39%1.99B
19.25%1B
13.65%3.65B
9.78%2.49B
8.62%1.63B
Operating tax surcharges
16.08%5.81M
6.71%3.79M
-8.22%1.88M
10.75%7.5M
10.06%5M
22.32%3.55M
36.69%2.05M
31.84%6.77M
22.64%4.55M
10.56%2.91M
Operating expense
26.37%180.91M
18.61%112.21M
22.78%53.86M
17.81%190.62M
33.05%143.16M
35.71%94.6M
26.65%43.87M
25.38%161.81M
12.14%107.59M
14.54%69.71M
Administration expense
14.72%48.26M
12.19%32.24M
28.81%16.04M
-3.63%57.47M
38.72%42.07M
45.56%28.74M
37.81%12.45M
68.21%59.63M
18.55%30.33M
2.28%19.74M
Financial expense
84.33%6.58M
95.41%4.1M
86.50%2.08M
-4.25%6.99M
-11.01%3.57M
-27.63%2.1M
-30.59%1.12M
231.37%7.3M
437.87%4.01M
488.34%2.9M
-Interest expense (Financial expense)
67.63%7.39M
121.85%5.08M
85.59%2.5M
2.46%6.58M
11.37%4.41M
-19.63%2.29M
8.43%1.35M
253.57%6.42M
--3.96M
551.61%2.85M
-Interest Income (Financial expense)
-18.01%-3.18M
-57.57%-2.49M
19.66%-1.08M
4.60%-2.27M
-62.23%-2.7M
-62.53%-1.58M
-390.75%-1.35M
-11.26%-2.38M
---1.66M
20.40%-970.97K
Research and development
-11.02%12.57M
1.09%9.32M
2.69%4.8M
9.11%19.32M
7.83%14.12M
6.50%9.22M
-6.12%4.67M
55.63%17.71M
--13.1M
--8.66M
Credit Impairment Loss
26.77%-15.38M
12.71%-16.14M
4.65%-17.06M
-13.33%-13.16M
-3.68%-21M
-7.61%-18.49M
-201.68%-17.89M
-431.23%-11.61M
-83.24%-20.26M
-57.50%-17.18M
Asset Impairment Loss
129.21%816.31K
157.10%684.53K
125.91%636.78K
-8.03%-9.09M
13.30%-2.79M
81.60%-1.2M
35.53%-2.46M
-96.15%-8.42M
-5.88%-3.22M
-112.18%-6.52M
Other net revenue
30.16%-14.14M
6.20%-15.33M
21.63%-15.71M
-13.76%-17.09M
-13.61%-20.25M
19.63%-16.34M
-176.39%-20.04M
-323.66%-15.03M
-520.61%-17.82M
-578.77%-20.34M
Invest income
-215.91%-468.07K
-196.52%-394.33K
-164.72%-20.45K
135.89%1.54M
126.31%403.82K
156.83%408.56K
122.36%31.6K
-157.08%-4.29M
-114.59%-1.54M
-106.83%-718.95K
-Including: Investment income associates
-183.32%-2.02M
-1,011.07%-1.5M
---556.09K
28.27%-862.51K
44.36%-713.58K
143.13%164.16K
----
-1,049.52%-1.2M
---1.28M
-105.27%-380.64K
Asset deal income
-35,167.54%-496.97K
-17,074.29%-598.65K
---31.61K
33.45%-52.69K
131.65%1.42K
476.49%3.53K
----
27.09%-79.18K
-98.38%611.77
-74.26%611.77
Other revenue
-55.81%1.39M
-61.85%1.12M
183.56%761.65K
-60.82%3.67M
-56.25%3.15M
-28.16%2.93M
-89.78%268.61K
61.98%9.37M
-7.48%7.2M
-46.95%4.08M
Operating profit
-82.96%10.23M
-84.73%8.52M
-81.26%6.45M
45.41%68.6M
314.23%60.05M
1,150.64%55.83M
259.17%34.41M
409.33%47.17M
-6.61%14.5M
-68.43%4.46M
Add:Non operating Income
-37.00%917.4K
-42.46%801.53K
42.78%65.89K
883.78%1.66M
492.79%1.46M
1,677.28%1.39M
-51.81%46.15K
800.12%168.26K
7,716.01%245.64K
5,328.70%78.38K
Less:Non operating expense
310.84%770.92K
113.92%494.3K
69.48%110.27K
-84.85%371.45K
-36.87%187.65K
543.05%231.07K
242.93%65.06K
112.09%2.45M
-48.62%297.25K
-85.57%35.93K
Total profit
-83.07%10.38M
-84.50%8.83M
-81.38%6.4M
55.67%69.88M
324.49%61.31M
1,164.65%56.99M
256.12%34.39M
452.54%44.89M
-3.37%14.44M
-67.56%4.51M
Less:Income tax cost
-100.79%-92.08K
-111.22%-1.16M
-116.22%-791.18K
49.73%13.11M
132.45%11.67M
244.56%10.34M
117.67%4.88M
527.42%8.75M
109.58%5.02M
68.27%3M
Net profit
-78.90%10.47M
-78.58%9.99M
-75.62%7.19M
57.11%56.77M
426.78%49.65M
2,996.33%46.65M
297.98%29.51M
437.01%36.14M
-24.92%9.42M
-87.56%1.51M
Net profit from continuing operation
-79.85%10.47M
-78.58%9.99M
-75.62%7.19M
57.11%56.77M
451.62%51.99M
2,996.33%46.65M
297.98%29.51M
437.01%36.14M
--9.42M
-87.56%1.51M
Net income from discontinuing operating
----
----
----
----
---2.34M
----
----
----
----
----
Less:Minority Profit
-576.04%-3.46M
-3,203.80%-2.1M
4.39%-2.03M
53.09%-2.76M
93.04%-511.55K
98.90%-63.7K
-23.36%-2.12M
-1,887.28%-5.88M
-568.66%-7.35M
-280.88%-5.78M
Net profit of parent company owners
-72.22%13.93M
-74.11%12.1M
-70.84%9.23M
41.69%59.53M
198.95%50.16M
540.72%46.72M
246.22%31.63M
556.48%42.02M
52.77%16.78M
-18.18%7.29M
Earning per share
Basic earning per share
-71.15%0.15
-73.47%0.13
-70.79%0.0964
40.91%0.62
188.89%0.52
512.50%0.49
230.00%0.33
528.57%0.44
50.00%0.18
-20.00%0.08
Diluted earning per share
-71.15%0.15
-73.47%0.13
-70.79%0.0964
40.91%0.62
188.89%0.52
512.50%0.49
230.00%0.33
528.57%0.44
50.00%0.18
-20.00%0.08
Other composite income
200.00%1.5M
1.5M
1.5M
-1.5M
Other composite income of parent company owners
----
----
----
200.00%1.5M
--1.5M
--1.5M
----
---1.5M
----
----
Other composite income of minority owners
----
----
----
--0
----
----
----
--0
----
----
Total composite income
-79.52%10.47M
-79.25%9.99M
-75.62%7.19M
68.22%58.27M
442.66%51.14M
3,095.68%48.15M
297.98%29.51M
414.77%34.64M
-24.92%9.42M
-87.56%1.51M
Total composite income of parent company owners
-73.03%13.93M
-74.91%12.1M
-70.84%9.23M
50.62%61.03M
207.87%51.65M
561.25%48.21M
246.22%31.63M
533.09%40.52M
52.77%16.78M
-18.18%7.29M
Total composite income of minority owners
-576.04%-3.46M
-3,203.80%-2.1M
4.39%-2.03M
53.09%-2.76M
93.04%-511.55K
98.90%-63.7K
-23.36%-2.12M
-1,887.28%-5.88M
-568.66%-7.35M
-280.88%-5.78M
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
Audit Opinions
--
--
--
Unqualified opinion
--
--
--
Unqualified opinion
--
--
Auditor
--
--
--
Lixin Certified Public Accountants (Special General Partnership)
--
--
--
Lixin Certified Public Accountants (Special General Partnership)
--
--
(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022
Total operating revenue 0.72%3.24B0.93%2.23B10.29%1.24B11.62%4.43B19.75%3.21B25.40%2.2B23.29%1.12B16.72%3.97B11.49%2.68B10.35%1.76B
Operating revenue 0.72%3.24B0.93%2.23B10.29%1.24B11.62%4.43B19.75%3.21B25.40%2.2B23.29%1.12B16.72%3.97B11.49%2.68B10.35%1.76B
Other operating revenue ----48.84%15.08M-----0.48%23.54M----7.48%10.13M----45.73%23.65M----719.53%9.43M
Total operating cost 2.52%3.21B3.23%2.2B13.84%1.22B11.20%4.34B18.18%3.13B23.03%2.13B19.52%1.07B14.98%3.91B10.66%2.65B9.47%1.73B
Operating cost 1.12%2.96B2.27%2.04B13.28%1.14B11.19%4.06B17.40%2.92B22.39%1.99B19.25%1B13.65%3.65B9.78%2.49B8.62%1.63B
Operating tax surcharges 16.08%5.81M6.71%3.79M-8.22%1.88M10.75%7.5M10.06%5M22.32%3.55M36.69%2.05M31.84%6.77M22.64%4.55M10.56%2.91M
Operating expense 26.37%180.91M18.61%112.21M22.78%53.86M17.81%190.62M33.05%143.16M35.71%94.6M26.65%43.87M25.38%161.81M12.14%107.59M14.54%69.71M
Administration expense 14.72%48.26M12.19%32.24M28.81%16.04M-3.63%57.47M38.72%42.07M45.56%28.74M37.81%12.45M68.21%59.63M18.55%30.33M2.28%19.74M
Financial expense 84.33%6.58M95.41%4.1M86.50%2.08M-4.25%6.99M-11.01%3.57M-27.63%2.1M-30.59%1.12M231.37%7.3M437.87%4.01M488.34%2.9M
-Interest expense (Financial expense) 67.63%7.39M121.85%5.08M85.59%2.5M2.46%6.58M11.37%4.41M-19.63%2.29M8.43%1.35M253.57%6.42M--3.96M551.61%2.85M
-Interest Income (Financial expense) -18.01%-3.18M-57.57%-2.49M19.66%-1.08M4.60%-2.27M-62.23%-2.7M-62.53%-1.58M-390.75%-1.35M-11.26%-2.38M---1.66M20.40%-970.97K
Research and development -11.02%12.57M1.09%9.32M2.69%4.8M9.11%19.32M7.83%14.12M6.50%9.22M-6.12%4.67M55.63%17.71M--13.1M--8.66M
Credit Impairment Loss 26.77%-15.38M12.71%-16.14M4.65%-17.06M-13.33%-13.16M-3.68%-21M-7.61%-18.49M-201.68%-17.89M-431.23%-11.61M-83.24%-20.26M-57.50%-17.18M
Asset Impairment Loss 129.21%816.31K157.10%684.53K125.91%636.78K-8.03%-9.09M13.30%-2.79M81.60%-1.2M35.53%-2.46M-96.15%-8.42M-5.88%-3.22M-112.18%-6.52M
Other net revenue 30.16%-14.14M6.20%-15.33M21.63%-15.71M-13.76%-17.09M-13.61%-20.25M19.63%-16.34M-176.39%-20.04M-323.66%-15.03M-520.61%-17.82M-578.77%-20.34M
Invest income -215.91%-468.07K-196.52%-394.33K-164.72%-20.45K135.89%1.54M126.31%403.82K156.83%408.56K122.36%31.6K-157.08%-4.29M-114.59%-1.54M-106.83%-718.95K
-Including: Investment income associates -183.32%-2.02M-1,011.07%-1.5M---556.09K28.27%-862.51K44.36%-713.58K143.13%164.16K-----1,049.52%-1.2M---1.28M-105.27%-380.64K
Asset deal income -35,167.54%-496.97K-17,074.29%-598.65K---31.61K33.45%-52.69K131.65%1.42K476.49%3.53K----27.09%-79.18K-98.38%611.77-74.26%611.77
Other revenue -55.81%1.39M-61.85%1.12M183.56%761.65K-60.82%3.67M-56.25%3.15M-28.16%2.93M-89.78%268.61K61.98%9.37M-7.48%7.2M-46.95%4.08M
Operating profit -82.96%10.23M-84.73%8.52M-81.26%6.45M45.41%68.6M314.23%60.05M1,150.64%55.83M259.17%34.41M409.33%47.17M-6.61%14.5M-68.43%4.46M
Add:Non operating Income -37.00%917.4K-42.46%801.53K42.78%65.89K883.78%1.66M492.79%1.46M1,677.28%1.39M-51.81%46.15K800.12%168.26K7,716.01%245.64K5,328.70%78.38K
Less:Non operating expense 310.84%770.92K113.92%494.3K69.48%110.27K-84.85%371.45K-36.87%187.65K543.05%231.07K242.93%65.06K112.09%2.45M-48.62%297.25K-85.57%35.93K
Total profit -83.07%10.38M-84.50%8.83M-81.38%6.4M55.67%69.88M324.49%61.31M1,164.65%56.99M256.12%34.39M452.54%44.89M-3.37%14.44M-67.56%4.51M
Less:Income tax cost -100.79%-92.08K-111.22%-1.16M-116.22%-791.18K49.73%13.11M132.45%11.67M244.56%10.34M117.67%4.88M527.42%8.75M109.58%5.02M68.27%3M
Net profit -78.90%10.47M-78.58%9.99M-75.62%7.19M57.11%56.77M426.78%49.65M2,996.33%46.65M297.98%29.51M437.01%36.14M-24.92%9.42M-87.56%1.51M
Net profit from continuing operation -79.85%10.47M-78.58%9.99M-75.62%7.19M57.11%56.77M451.62%51.99M2,996.33%46.65M297.98%29.51M437.01%36.14M--9.42M-87.56%1.51M
Net income from discontinuing operating -------------------2.34M--------------------
Less:Minority Profit -576.04%-3.46M-3,203.80%-2.1M4.39%-2.03M53.09%-2.76M93.04%-511.55K98.90%-63.7K-23.36%-2.12M-1,887.28%-5.88M-568.66%-7.35M-280.88%-5.78M
Net profit of parent company owners -72.22%13.93M-74.11%12.1M-70.84%9.23M41.69%59.53M198.95%50.16M540.72%46.72M246.22%31.63M556.48%42.02M52.77%16.78M-18.18%7.29M
Earning per share
Basic earning per share -71.15%0.15-73.47%0.13-70.79%0.096440.91%0.62188.89%0.52512.50%0.49230.00%0.33528.57%0.4450.00%0.18-20.00%0.08
Diluted earning per share -71.15%0.15-73.47%0.13-70.79%0.096440.91%0.62188.89%0.52512.50%0.49230.00%0.33528.57%0.4450.00%0.18-20.00%0.08
Other composite income 200.00%1.5M1.5M1.5M-1.5M
Other composite income of parent company owners ------------200.00%1.5M--1.5M--1.5M-------1.5M--------
Other composite income of minority owners --------------0--------------0--------
Total composite income -79.52%10.47M-79.25%9.99M-75.62%7.19M68.22%58.27M442.66%51.14M3,095.68%48.15M297.98%29.51M414.77%34.64M-24.92%9.42M-87.56%1.51M
Total composite income of parent company owners -73.03%13.93M-74.91%12.1M-70.84%9.23M50.62%61.03M207.87%51.65M561.25%48.21M246.22%31.63M533.09%40.52M52.77%16.78M-18.18%7.29M
Total composite income of minority owners -576.04%-3.46M-3,203.80%-2.1M4.39%-2.03M53.09%-2.76M93.04%-511.55K98.90%-63.7K-23.36%-2.12M-1,887.28%-5.88M-568.66%-7.35M-280.88%-5.78M
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions ------Unqualified opinion------Unqualified opinion----
Auditor ------Lixin Certified Public Accountants (Special General Partnership)------Lixin Certified Public Accountants (Special General Partnership)----

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Top CN Stock Gainers
Symbol Price % Chg
KAYO MOTOR
834058
38.58 +29.99%
Zhejiang Zoenn Design
300901
14.86 +20.03%
Zhejiang Meorient Commerce & Exhibition Inc.
300795
22.36 +20.02%
Fujian Zitian Media Technology
300280
22.18 +20.02%
Zhejiang Prulde Electric Appliance
301353
36.46 +20.01%

See the daily top gainer.

Investment Theme Pharmaceutical E-commerce
Pharmaceutical E-commerce
Intraday-1.88%